Yaron Werber
Stock Analyst at TD Cowen
(2.48)
# 3,313
Out of 5,182 analysts
44
Total ratings
43.75%
Success rate
4.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yaron Werber
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Maintains: Buy | $51 → $55 | $48.16 | +14.20% | 4 | May 6, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $110 → $108 | $75.71 | +42.65% | 3 | Apr 23, 2026 | |
| BNTX BioNTech SE | Maintains: Hold | $116 → $94 | $94.13 | -0.13% | 6 | Mar 11, 2026 | |
| LEGN Legend Biotech | Downgrades: Hold | $62 → $21 | $28.12 | -25.32% | 3 | Jan 22, 2026 | |
| VOR Vor Biopharma | Initiates: Buy | n/a | $16.94 | - | 1 | Dec 17, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $86 → $75 | $26.12 | +187.14% | 3 | Nov 5, 2025 | |
| ARGX argenx SE | Maintains: Buy | $800 → $1,146 | $782.17 | +46.52% | 4 | Oct 31, 2025 | |
| ALEC Alector | Downgrades: Hold | n/a | $2.10 | - | 1 | Oct 22, 2025 | |
| ONC BeOne Medicines AG | Reiterates: Buy | $334 | $312.12 | +7.01% | 1 | Apr 24, 2025 | |
| FBRX Forte Biosciences | Initiates: Buy | n/a | $24.02 | - | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $86.71 | - | 1 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $23.87 | - | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $153 | $238.66 | -35.89% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $9.09 | - | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $32.89 | - | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.93 | - | 1 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $5.22 | - | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $33.97 | - | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $8.16 | - | 2 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $38 | $26.43 | +43.78% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $28.56 | - | 1 | Oct 26, 2021 |
Exelixis
May 6, 2026
Maintains: Buy
Price Target: $51 → $55
Current: $48.16
Upside: +14.20%
Ionis Pharmaceuticals
Apr 23, 2026
Maintains: Buy
Price Target: $110 → $108
Current: $75.71
Upside: +42.65%
BioNTech SE
Mar 11, 2026
Maintains: Hold
Price Target: $116 → $94
Current: $94.13
Upside: -0.13%
Legend Biotech
Jan 22, 2026
Downgrades: Hold
Price Target: $62 → $21
Current: $28.12
Upside: -25.32%
Vor Biopharma
Dec 17, 2025
Initiates: Buy
Price Target: n/a
Current: $16.94
Upside: -
Ultragenyx Pharmaceutical
Nov 5, 2025
Maintains: Buy
Price Target: $86 → $75
Current: $26.12
Upside: +187.14%
argenx SE
Oct 31, 2025
Maintains: Buy
Price Target: $800 → $1,146
Current: $782.17
Upside: +46.52%
Alector
Oct 22, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.10
Upside: -
BeOne Medicines AG
Apr 24, 2025
Reiterates: Buy
Price Target: $334
Current: $312.12
Upside: +7.01%
Forte Biosciences
Jan 21, 2025
Initiates: Buy
Price Target: n/a
Current: $24.02
Upside: -
Dec 20, 2024
Initiates: Buy
Price Target: n/a
Current: $86.71
Upside: -
Nov 19, 2024
Initiates: Buy
Price Target: n/a
Current: $23.87
Upside: -
Nov 15, 2024
Maintains: Buy
Price Target: $160 → $153
Current: $238.66
Upside: -35.89%
Nov 5, 2024
Initiates: Buy
Price Target: n/a
Current: $9.09
Upside: -
Mar 26, 2024
Upgrades: Buy
Price Target: n/a
Current: $32.89
Upside: -
Mar 18, 2024
Initiates: Outperform
Price Target: n/a
Current: $0.93
Upside: -
Mar 15, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $5.22
Upside: -
Dec 20, 2023
Initiates: Outperform
Price Target: n/a
Current: $33.97
Upside: -
Nov 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $8.16
Upside: -
May 2, 2022
Initiates: Market Perform
Price Target: $38
Current: $26.43
Upside: +43.78%
Oct 26, 2021
Initiates: Outperform
Price Target: n/a
Current: $28.56
Upside: -